KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $29.0 million.

  • Royalty Pharma's Accumulated Expenses fell 2438.82% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 2438.82%. This contributed to the annual value of $98.1 million for FY2024, which is 8974.11% up from last year.
  • Royalty Pharma's Accumulated Expenses amounted to $29.0 million in Q3 2025, which was down 2438.82% from $85.6 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Accumulated Expenses peaked at $98.1 million during Q4 2024, and registered a low of $10.3 million during Q1 2021.
  • In the last 5 years, Royalty Pharma's Accumulated Expenses had a median value of $38.4 million in 2024 and averaged $38.6 million.
  • Per our database at Business Quant, Royalty Pharma's Accumulated Expenses skyrocketed by 20497.82% in 2024 and then tumbled by 2438.82% in 2025.
  • Over the past 5 years, Royalty Pharma's Accumulated Expenses (Quarter) stood at $57.7 million in 2021, then fell by 6.13% to $54.2 million in 2022, then fell by 4.58% to $51.7 million in 2023, then skyrocketed by 89.74% to $98.1 million in 2024, then tumbled by 70.38% to $29.0 million in 2025.
  • Its Accumulated Expenses stands at $29.0 million for Q3 2025, versus $85.6 million for Q2 2025 and $19.2 million for Q1 2025.